Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy

NCT02033616 is registered in ClinicalTrials.gov with Aivita Biomedical, Inc. as lead sponsor.

NCT NCT02033616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02033616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
Lead sponsor
Aivita Biomedical, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
November 18, 2017
Completion date
March 31, 2023
Enrollment
99 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube carcinoma, primary peritoneal carcinoma, stage iii ovarian carcinoma, stage iv ovarian carcinoma